Akero Therapeutics Inc [AKRO] stock is trading at $29.34, up 4.79%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AKRO shares have gain 4.79% over the last week, with a monthly amount glided 11.47%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on September 19, 2023, and set its price target to $69. On August 28, 2023, UBS initiated with a Buy rating and assigned a price target of $83 on the stock. Morgan Stanley upgraded its rating to a Overweight and increased its price target to $65 on January 27, 2023. Evercore ISI upgraded its rating to a Outperform and raised its price target to $50 on September 14, 2022. Morgan Stanley downgraded its rating to Equal-Weight for this stock on October 19, 2021, but kept the price target unchanged to $27. In a note dated September 10, 2021, BofA Securities initiated an Buy rating and provided a target price of $40 on this stock.
Akero Therapeutics Inc [AKRO] stock has fluctuated between $11.25 and $51.24 over the past year. Currently, Wall Street analysts expect the stock to reach $46 within the next 12 months. Akero Therapeutics Inc [NASDAQ: AKRO] shares were valued at $29.34 at the most recent close of the market. An investor can expect a potential return of 56.78% based on the average AKRO price forecast.
Analyzing the AKRO fundamentals
Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -824.59%, Pretax Profit Margin comes in at -718.93%, and Net Profit Margin reading is -718.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.3 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 28.45 points at the first support level, and at 27.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.91, and for the 2nd resistance point, it is at 30.49.
Ratios To Look Out For
For context, Akero Therapeutics Inc’s Current Ratio is 24.89. Further, the Quick Ratio stands at 24.89, while the Cash Ratio is 9.96.
Transactions by insiders
Recent insider trading involved Yale Catriona, Chief Development Officer, that happened on Sep 20 ’24 when 5500.0 shares were sold. Chief Development Officer, Yale Catriona completed a deal on Sep 18 ’24 to sell 3871.0 shares. Meanwhile, Chief Development Officer Yale Catriona sold 2485.0 shares on Sep 16 ’24.
